SCHEMBL24371639

SCHEMBL24371639

O=C(/C=C/CN1CCOCC1)NI

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HIF1A Q16665 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
EGFR P00533 4/20 0.37
ERBB2 P04626 2/20 0.37
GLA P06280 1/20 0.37
BTK Q06187 2/20 0.36
JAK3 P52333 1/20 0.35
ERBB4 Q15303 1/20 0.35
PLCG1 P19174 1/20 0.35
CDK7 P50613 1/20 0.35
CDK13 Q14004 1/20 0.35
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27451922 0.84 MEN1 (0.41) SMN1; SMN2HSD17B10KDM4EALOX15TSHR
SCHEMBL27451925 0.84 MEN1 (0.41) SMN1; SMN2HSD17B10KDM4EALOX15TSHR
SCHEMBL14079971 0.84 MEN1 (0.41) SMN1; SMN2HSD17B10KDM4EALOX15TSHR
SCHEMBL25583715 0.84 EGFR (0.33) MEN1KMT2AEGFRERBB2BTK
SCHEMBL23336391 0.83 KDM4E (0.43) SMN1; SMN2HSD17B10KDM4EALOX15TSHR
SCHEMBL25583718 0.82 ALDH1A1 (0.36) SMN1; SMN2MAPK1MEN1KMT2AEGFR
SCHEMBL17282927 0.80 KDM4E (0.42) SMN1; SMN2HSD17B10KDM4EALOX15TSHR
SCHEMBL20927103 0.80 HTT (0.49) SMN1; SMN2HSD17B10KDM4ETSHRMAPK1
SCHEMBL19669736 0.80 MEN1 (0.45) SMN1; SMN2HSD17B10KDM4EMAPK1HIF1A
SCHEMBL15600841 0.79 SMN1; SMN2 (0.53) SMN1; SMN2HSD17B10KDM4EALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302448-B1 SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2023-10-25 EP disclosed
WO-2022084930-A2 CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-04-28 WO disclosed